Oncologic Outcomes After Liver Transplantation for Unresectable Colorectal Liver Metastases: A Systematic Review and Meta-Analysis of Proportions.

J Surg OncolJun 17, 2026 (epub)
Clinical ResearchOncology (Medical)General SurgeryOpen access

Bernardo Fontel Pompeu, Lorrany Ramos Aguiar, Giuliana Daneluci Melillo et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis assessed oncologic outcomes in 92 patients with unresectable colorectal liver metastases who underwent liver transplantation. The study found that the one-year overall survival rate was 96.32%, while the three-year overall survival rate was 73.07%. Disease-free survival was notably lower, with significant recurrence rates observed.

Key findings

  • One-year overall survival rate was 96.32%.
  • Three-year overall survival rate was 73.07%.
  • Disease-free survival was lower, with high recurrence rates.
  • Major complications occurred in 39.36% of patients.

Why it matters

Understanding the oncologic outcomes of liver transplantation for unresectable colorectal liver metastases is crucial for clinicians to evaluate this treatment option's viability and to refine patient selection criteria.

Source

PubMed · PMID 42306995Free full text on PubMed Central

Published in J Surg Oncol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.